Lundbeck Takes A Singular View Toward Tackling Challenging CNS Disorders
Executive Summary
The Danish drug maker has focused R&D on four CNS specialties under its new CEO and is moving forward two late-stage programs for symptoms of Alzheimer’s disease. Exec VP-Lundbeck Research, USA Stevin Zorn discusses the firm’s R&D strategy in an interview.
You may also be interested in...
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.
Regeneron Oncology Setback Delivered By US FDA Crackdown On Accelerated Approval
The company received two complete response letters from the US FDA for the CD20xCD3 bispecific antibody odronextamab due to clinical trial requirements for accelerated approval.